PT2900254T - Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias - Google Patents
Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias Download PDFInfo
- Publication number
- PT2900254T PT2900254T PT137599957T PT13759995T PT2900254T PT 2900254 T PT2900254 T PT 2900254T PT 137599957 T PT137599957 T PT 137599957T PT 13759995 T PT13759995 T PT 13759995T PT 2900254 T PT2900254 T PT 2900254T
- Authority
- PT
- Portugal
- Prior art keywords
- deficiency
- aim
- mitochondrial
- microglobulin
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2900254T true PT2900254T (pt) | 2016-10-18 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137599957T PT2900254T (pt) | 2012-09-05 | 2013-09-04 | Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (enExample) |
| EP (1) | EP2900254B1 (enExample) |
| JP (2) | JP2015533790A (enExample) |
| KR (1) | KR20150047510A (enExample) |
| CN (1) | CN104661673A (enExample) |
| AU (1) | AU2013311714C1 (enExample) |
| BR (1) | BR112015003957A2 (enExample) |
| CA (1) | CA2881321A1 (enExample) |
| DK (1) | DK2900254T3 (enExample) |
| EA (1) | EA028963B1 (enExample) |
| ES (1) | ES2599034T3 (enExample) |
| HR (1) | HRP20161364T1 (enExample) |
| HU (1) | HUE030559T2 (enExample) |
| IN (1) | IN2015DN00515A (enExample) |
| MX (1) | MX357656B (enExample) |
| NZ (1) | NZ629621A (enExample) |
| PL (1) | PL2900254T3 (enExample) |
| PT (1) | PT2900254T (enExample) |
| SG (1) | SG11201500669SA (enExample) |
| WO (1) | WO2014037390A1 (enExample) |
| ZA (1) | ZA201500547B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| US20190054142A1 (en) * | 2016-02-25 | 2019-02-21 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| US10981963B2 (en) * | 2016-03-18 | 2021-04-20 | Guard Therapeutics International AB | Alpha-1-microglobulin derived proteins and their use |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547124A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| EA022609B1 (ru) * | 2007-02-12 | 2016-02-29 | А1М Фарма Аб | Применение свободного фетального гемоглобина в качестве маркера преэклампсии |
| ES2560097T3 (es) * | 2008-02-04 | 2016-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Procedimientos y composiciones de tratamiento de trastornos mitocondriales |
| CA2730531A1 (en) * | 2008-07-18 | 2010-01-21 | A1M Pharma Ab | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en not_active Ceased
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA028963B1 (ru) | 2018-01-31 |
| MX357656B (es) | 2018-07-18 |
| KR20150047510A (ko) | 2015-05-04 |
| AU2013311714A1 (en) | 2015-03-12 |
| PL2900254T3 (pl) | 2017-02-28 |
| JP2015533790A (ja) | 2015-11-26 |
| US10226507B2 (en) | 2019-03-12 |
| MX2015002604A (es) | 2015-06-10 |
| AU2013311714C1 (en) | 2018-01-25 |
| CN104661673A (zh) | 2015-05-27 |
| HRP20161364T1 (hr) | 2016-12-16 |
| NZ629621A (en) | 2015-09-25 |
| WO2014037390A1 (en) | 2014-03-13 |
| US20150258171A1 (en) | 2015-09-17 |
| JP2018203756A (ja) | 2018-12-27 |
| IN2015DN00515A (enExample) | 2015-06-26 |
| EP2900254B1 (en) | 2016-08-03 |
| CA2881321A1 (en) | 2014-03-13 |
| DK2900254T3 (en) | 2016-08-29 |
| HK1210585A1 (en) | 2016-04-29 |
| EP2900254A1 (en) | 2015-08-05 |
| AU2013311714B2 (en) | 2017-10-12 |
| ZA201500547B (en) | 2017-09-27 |
| ES2599034T3 (es) | 2017-01-31 |
| BR112015003957A2 (pt) | 2017-08-08 |
| SG11201500669SA (en) | 2015-02-27 |
| HUE030559T2 (en) | 2017-05-29 |
| EA201590503A1 (ru) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2599034T3 (es) | Alfa-1-microglobulina para su uso en el tratamiento de enfermedades relacionadas con mitocondrias | |
| Reddy et al. | Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases | |
| Britti et al. | Frataxin‐deficient neurons and mice models of Friedreich ataxia are improved by TAT‐MTS cs‐FXN treatment | |
| US10624948B2 (en) | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases | |
| Park et al. | Fusion of lysosomes with secretory organelles leads to uncontrolled exocytosis in the lysosomal storage disease mucolipidosis type IV | |
| Hughes et al. | Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy | |
| BRPI0211200B1 (pt) | Peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| CN104023736A (zh) | Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途 | |
| Bollag et al. | Dioleoylphosphatidylglycerol accelerates corneal epithelial wound healing | |
| CN107969126A (zh) | Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途 | |
| Formichi et al. | Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene | |
| US7790673B2 (en) | Methods and compositions relating to cystatin C | |
| ES2868354T3 (es) | Péptido Naktide para el tratamiento de la obesidad | |
| Argenti | The role of mitochondrial dysfunction in Huntington's disease: pathogenesis and its relation with striatal Rhes protein | |
| HK1210585B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| Petese et al. | Are Lysosomes Potential Therapeutic Targets for Parkinson’s Disease? | |
| Jones | The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult | |
| Vijayasarathy et al. | Organization and molecular interactions of retinoschisin in photoreceptors | |
| Alassaf | Pregnancy associated plasma protein-aa is a novel regulator of neuron survival | |
| Faber et al. | Gene augmentation of LCA5-Leber congenital amaurosis ameliorates bulge region defects of the photoreceptor ciliary axoneme | |
| US20190099468A1 (en) | Method to protect and seal the ocular surface | |
| KR101481741B1 (ko) | Ⅰｇｆ１을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법 | |
| CN121127256A (zh) | 作为有效成分包含Prdx3的线粒体相关疾病预防或治疗用组合物及其用途 | |
| Choudhury | Involvement of Caspase-7 in photoreceptor and retinal ganglion cell death | |
| Song | Defective Dynamics Of Mitochondria In Amyotrophic Lateral Sclerosis And Huntington's Disease |